{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T21:50:12Z","timestamp":1775339412428,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by slowly progressive bilateral renal cyst growth ultimately resulting in loss of kidney function and end-stage renal disease (ESRD). Disease progression rate and age at ESRD are highly variable. Therapeutic interventions therefore require early risk stratification of patients and monitoring of disease progression in response to treatment.<\/jats:p>\n                  <jats:p>Methods: We used a urine peptidomic approach based on capillary electrophoresis\u2013mass\u2013spectrometry (CE-MS) to identify potential biomarkers reflecting the risk for early progression to ESRD in the Consortium of Radiologic Imaging in Polycystic Kidney Disease (CRISP) cohort.<\/jats:p>\n                  <jats:p>Results: A biomarker-based classifier consisting of 20 urinary peptides allowed the prediction of ESRD within 10\u201313 years of follow-up in patients 24\u201346 years of age at baseline. The performance of the biomarker score approached that of height-adjusted total kidney volume (htTKV) and the combination of the biomarker panel with htTKV improved prediction over either one alone. In young patients (&amp;lt;24 years at baseline), the same biomarker model predicted a 30 mL\/min\/1.73 m2 glomerular filtration rate decline over 8 years. Sequence analysis of the altered urinary peptides and the prediction of the involved proteases by in silico analysis revealed alterations in distinct proteolytic pathways, in particular matrix metalloproteinases and cathepsins.<\/jats:p>\n                  <jats:p>Conclusion: We developed a urinary test that accurately predicts relevant clinical outcomes in ADPKD patients and suggests altered proteolytic pathways involved in disease progression.<\/jats:p>","DOI":"10.1093\/ndt\/gfw243","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T21:19:08Z","timestamp":1467753548000},"page":"487-497","source":"Crossref","is-referenced-by-count":8,"title":["Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression"],"prefix":"10.1093","volume":"32","author":[{"given":"Martin","family":"Pejchinovski","sequence":"first","affiliation":[{"name":"1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany"},{"name":"2Charite-Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Siwy","sequence":"additional","affiliation":[{"name":"1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Metzger","sequence":"additional","affiliation":[{"name":"1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Dakna","sequence":"additional","affiliation":[{"name":"1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[{"name":"1Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany"},{"name":"3BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Klein","sequence":"additional","affiliation":[{"name":"4Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1048, Toulouse, France"},{"name":"5Universit\u00e9 Toulouse III Paul-Sabatier, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Jankowski","sequence":"additional","affiliation":[{"name":"6Universit\u00e4tsklinikum RWTH Aachen, Institute of Molecular Cardiovascular Research, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyongtae T.","family":"Bae","sequence":"additional","affiliation":[{"name":"7Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[{"name":"8Section of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USA and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas D.","family":"Kistler","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Renal Unit, Cantonal Hospital Frauenfeld, Pfaffenholzstrasse 4, 8501 Frauenfeld, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"2025102312500632400_gfw243C1","first-page":"1","article-title":"Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families","volume":"328","author":"Dalgaard","year":"1957","journal-title":"Acta Med Scand Suppl"},{"key":"2025102312500632400_gfw243C2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935\u20131980","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"2025102312500632400_gfw243C3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"key":"2025102312500632400_gfw243C5","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1681\/ASN.V7102142","article-title":"Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2","volume":"7","author":"Torra","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C6","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group","volume":"5","author":"Klahr","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12136","article-title":"New treatments for autosomal dominant polycystic kidney disease","volume":"76","author":"Chang","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2025102312500632400_gfw243C8","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"2025102312500632400_gfw243C9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/ki.2012.146","article-title":"Urinary biomarkers in autosomal dominant polycystic kidney disease: is there no prognostic value?","volume":"82","author":"Boertien","year":"2012","journal-title":"Kidney Int"},{"key":"2025102312500632400_gfw243C11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000103912","article-title":"Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease","volume":"27","author":"Bolignano","year":"2007","journal-title":"Am J Nephrol"},{"key":"2025102312500632400_gfw243C12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis","volume":"56","author":"Meijer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2025102312500632400_gfw243C13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ki.2011.465","article-title":"Evaluation of urine biomarkers of kidney injury in polycystic kidney disease","volume":"81","author":"Parikh","year":"2012","journal-title":"Kidney Int"},{"key":"2025102312500632400_gfw243C14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2369-13-93","article-title":"Urinary N-acetyl-beta-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study","volume":"13","author":"Park","year":"2012","journal-title":"BMC Nephrol"},{"key":"2025102312500632400_gfw243C15","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C17","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","article-title":"Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease","volume":"27","author":"Boertien","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500632400_gfw243C18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2025102312500632400_gfw243C19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mas.20205","article-title":"Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments","volume":"28","author":"Mischak","year":"2009","journal-title":"Mass Spectrom Rev"},{"key":"2025102312500632400_gfw243C20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ki.2009.93","article-title":"Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease","volume":"76","author":"Kistler","year":"2009","journal-title":"Kidney Int"},{"key":"2025102312500632400_gfw243C21","doi-asserted-by":"crossref","first-page":"e53016","DOI":"10.1371\/journal.pone.0053016","article-title":"Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study","volume":"8","author":"Kistler","year":"2013","journal-title":"PLoS One"},{"key":"2025102312500632400_gfw243C22","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"2025102312500632400_gfw243C23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"2025102312500632400_gfw243C24","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1681\/ASN.2014050423","article-title":"Diagnosis and prediction of CKD progression by assessment of urinary peptides","volume":"26","author":"Schanstra","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025102312500632400_gfw243C25","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/pmic.201200493","article-title":"Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally-occurring peptide generation","volume":"13","author":"Klein","year":"2013","journal-title":"Proteomics"},{"key":"2025102312500632400_gfw243C26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","article-title":"ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"2025102312500632400_gfw243C27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/bioinformatics\/btt019","article-title":"CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data","volume":"29","author":"Bindea","year":"2013","journal-title":"Bioinformatics"},{"key":"2025102312500632400_gfw243C28","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1002\/pmic.201100066","article-title":"Reactome pathway analysis to enrich biological discovery in proteomics data sets","volume":"11","author":"Haw","year":"2011","journal-title":"Proteomics"},{"key":"2025102312500632400_gfw243C29","first-page":"125","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B (Method)"},{"key":"2025102312500632400_gfw243C30","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1074\/mcp.M110.001917","article-title":"Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease","volume":"9","author":"Good","year":"2010","journal-title":"Mol Cell Proteomics"},{"key":"2025102312500632400_gfw243C31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/prca.200800163","article-title":"The biomarker enriched proteome of autosomal dominant polycystic kidney disease cyst fluid","volume":"3","author":"Mason","year":"2009","journal-title":"Proteomics Clin Appl"},{"key":"2025102312500632400_gfw243C32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/ndt\/gfm697","article-title":"Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease","volume":"23","author":"Berthier","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025102312500632400_gfw243C33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000013552","article-title":"Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease","volume":"20","author":"Nakamura","year":"2000","journal-title":"Am J Nephrol"},{"key":"2025102312500632400_gfw243C34","doi-asserted-by":"crossref","first-page":"F540","DOI":"10.1152\/ajprenal.2001.280.3.F540","article-title":"A possible role for metalloproteinases in renal cyst development","volume":"280","author":"Obermuller","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102312500632400_gfw243C35","doi-asserted-by":"crossref","first-page":"F1725","DOI":"10.1152\/ajprenal.90420.2008","article-title":"Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1","volume":"295","author":"Alcalay","year":"2008","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/3\/487\/17822414\/gfw243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/32\/3\/487\/17822414\/gfw243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:12Z","timestamp":1761238272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/32\/3\/487\/3059457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,7,5]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfw243","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2016,7,5]]}}}